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P R E V I E W S
Given the enormous literature that
encompasses signal transduction
research, it is daunting to consider how
much still remains to be learned. While
some questions have received consider-
able attention, many others have barely
been touched. For example, in cancer,
we have gained a broad outline of the
major signaling pathways that control
cancer pathophysiology (sometimes
referred to in cartoon form as roadmaps
or subway maps). However, we know lit-
tle about the signal trafficking pathways
that dictate how signal transduction mol-
ecules are moved about in cells and how
such trafficking pathways may be
hijacked in cancer. By controlling the
movement of signaling molecules, signal
trafficking molecules can control the effi-
ciency of information transfer along a
pathway—in digital terms, the informa-
tion “bandwidth” rather than the 
information itself. This distinction is
important because signal trafficking is an
obvious realm for modifier effects: one
should expect this realm to become
more important to cancer investigations
given mounting evidence from mouse
genetics and human epidemiological
studies that modifier effects can domi-
nate signaling by tumor suppressors and
oncogenes (Dove, 2003; Dragani, 2003).
Another illustration of the work yet to be
done comes from consider-
ing how little we know about
how the major signaling
pathways influence most of
the systems that make up
cellular physiology. For
example, in cancer, a large
number of studies have
focused on how the major
signaling pathways control
transcription. In contrast,
fewer studies have focused
on how these pathways 
control other fundamental
processes, such as transla-
tion, membrane dynamics,
and energy metabolism (to
name only a few). Thus,
although it might seem as
though our knowledge about
signal transduction in cancer is fairly
extensive, the existing knowledge proba-
bly represents only a small tip of the ice-
berg of what remains to be learned.
Given this situation, one would
expect significant new perspectives on
signal transduction in cancer to continue
to emerge. One example is offered by a
recent report on Ras and Akt signaling
published by Eric Holland and col-
leagues in Molecular Cell (Rajasekhar et
al., 2003). Reference to signaling
roadmaps might lead some investigators
to think that the primary effect of Ras/Akt
signaling on gene expression is mediat-
ed by altering the transcription of down-
stream target genes. However, the
results of Holland and colleagues argue
that the primary effect of Ras/Akt on
gene expression occurs mainly at the
level of translation. Specifically, when
Ras/Akt signaling was augmented or dis-
rupted in primary brain cells, there was a
rapid change in the pattern of mRNAs
loaded onto polysomes, the factories of
ribosomes that mediate efficient transla-
tion of many cellular messages. This
response was documented by gene
microarray analysis of polysomal RNAs
that were fractionated from total RNA
isolated from cells under different condi-
tions. Using a 12,488-gene microarray
and a 3-fold cutoff, 705 mRNAs were
found to be differentially loaded onto
polysomes in cells where signaling was
augmented by ectopic expression of acti-
vated K-Ras and/or Akt (a myristoylated
Akt construct). This set of mRNAs was
then compared in two ways to the
mRNAs that were loaded onto
polysomes when Ras/Akt signaling was
disrupted in stably transformed cells by
small molecule inhibitors of MEK, PI3K,
or mTOR (three downstream effectors of
Ras and Akt signaling). By comparing
the different sets of mRNAs identified, a
“union set” of 426 mRNAs was judged to
be regulated by Ras/Akt at the level of
polysomal loading. Slightly more than
half of the mRNAs identified represented
known genes, which encompassed a
wide spectrum of functions (Rajasekhar
et al., 2003).
Notably, changes in polysomal load-
ing patterns of these mRNAs occurred
rapidly upon Ras/Akt blockade, within 2
hr of inhibitor addition. In contrast, during
the same period, there was little effect on
the complexity of total cellular RNA that
would be affected by transcriptional
changes (such changes were apparent
by 24 hr as would be expected, howev-
er). Thus, it appeared that Ras/Akt sig-
naling acted on gene expression and cell
transformation primarily at the level of
translation by altering the composition of
mRNAs loaded onto actively
translating polysomes. The
likelihood that translational
effects preceded transcrip-
tional effects was reinforced
by the finding that transcrip-
tion factors were encoded by
?20% of the mRNAs that
were differentially recruited to
ribosomes within 2 hr of 
Ras/Akt blockade (Rajasekhar
et al., 2003).
This study extends the
evidence that translational
modulation by Ras and Akt 
is necessary and perhaps 
in some cases even 
sufficient for cell transforma-
tion. Activated Ras stimulates
through ERK the activation of
Figure 1. Ras/Akt signaling to translation
Ras signaling through ERK and Akt signaling through mTOR lead to the
control of translational effects at the level of cap-dependent recruit-
ment of mRNAs to polysomes and perhaps other cap-independent
effects. Patterns of polysomal mRNA recruitment are altered rapidly,
before the complexity of total cellular RNA is altered significantly by
changes in transcription patterns. Holland and colleagues observed
that ?20% of the mRNAs influenced by Ras/Akt at the level of polyso-
mal recruitment encoded transcription factors (Rajasekhar et al.,
2003), in support of the idea that translational effects may precede
transcriptional effects of Ras/Akt signaling.
Signal transduction: Putting translation before transcription
A recent microarray-based study shows that Ras/Akt signaling rapidly alters the pattern of existing mRNAs that are recruit-
ed to polysomes. This response precedes the effects of transcription on total cellular RNA, suggesting that the primary
effect of Ras/Akt signaling on gene expression may occur mainly at the level of translation.
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Malignancies involving the upper gas-
trointestinal tract (esophagus, gastric,
biliary, liver, and pancreas) represent
some of the most biologically aggressive
and therapeutically challenging cancers.
In the United States, the number of
patients diagnosed with these cancers in
2003 has been estimated at 70,000 with
approximately 54,000 deaths. Pancreatic
cancer alone will account for 30,000
deaths this year and remains one of the
most treatment-refractory cancers
despite aggressive use of conventional
modalities such as surgery, radiation
therapy, or chemotherapy.
Originally described in Drosophila,
the hedgehog (Hh) signaling pathway is
one of the most fundamental in embry-
onic development. Three mammalian Hh
genes have been identified (sonic Hh
[SHh], Indian Hh [IHh], and desert Hh
[DHh]). Generally, this signal transduc-
tion pathway is responsible for patterning
numerous structures including the axial
skeleton, neural tube, limbs, lungs, skin,
hair, and teeth. In addition, SHh has
been demonstrated to be essential to
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Developmental biology informs cancer:The emerging role of the
hedgehog signaling pathway in upper gastrointestinal cancers
The hedgehog (Hh) signaling pathway plays many roles in invertebrate and vertebrate development. For example, specific
inhibition of sonic Hh expression is critical during early stages of pancreas organogenesis, but an active Hh pathway
appears to be required for maintenance of adult endocrine functions. Mutational inactivation of the Hh pathway has been
demonstrated in human malignancies of the skin, cerebellum, and skeletal muscle. Now, two papers implicate aberrant Hh
signaling in human upper gastrointestinal cancers including those developing from the esophagus, stomach, biliary tract,
and pancreas.
the mRNA cap binding translation initia-
tion factor eIF-4E (Gingras et al., 2001).
Strikingly, ectopic expression of eIF-4E
is sufficient to phenocopy the ability of
activated Ras to transform primary
rodent cells in cooperation with Myc or
E1A (Lazaris-Karatzas and Sonenberg,
1992). eIF-4E is inhibited by binding to
4E-BP and a set of related proteins, and
this inhibition is relieved by Akt signaling
through mTOR at the level of 4E-BP
phosphorylation (Gingras et al., 1999).
eIF-4E and 4E-BP have opposing effects
on apoptosis, including roles in
mediating the antiapoptotic effects of
activated Ras (Polunovsky et al., 1996,
2000). Interestingly, recent work 
suggests that malignant transformation 
may be associated with a higher require-
ment for cap-dependent translation to
inhibit apoptosis (Li et al., 2002). The
Akt/mTOR pathway also activates the
key translational regulatory kinase
p70S6K (Jefferies et al., 1997), and the
ability of Akt to transform cells is tightly
linked to upregulation of p70S6K and
downregulation of 4E-BP (Aoki et al.,
2001). Taken together, these and other
studies reveal a causal association
between cell transformation and transla-
tional control by Ras/Akt signaling.
Holland and colleagues advance the
association between Ras/Akt signaling
and translation in cancer cells in two
ways: first, by showing that Ras/Akt sig-
naling rapidly influences the patterns of
mRNA loading on polysomes and sec-
ond, by defining the identity of a large set
of genes that are regulated in this man-
ner. As many receptor signaling path-
ways impinge on Ras and Akt, and
thereby on translation initiation factors, it
will be interesting to learn how much
overlap there may be in the genes sub-
jected to regulation at the level of polyso-
mal mRNA recruitment. Furthermore,
given the rapidity with which cells can
respond to signaling through this level of
regulation, it will be interesting to learn
whether other signal transduction path-
ways use the same mechanism to drive
transcription-independent programs of
gene expression.
George C. Prendergast*
Lankenau Institute for Medical Research
and Department of Pathology,
Anatomy, and Cell Biology
Jefferson Medical School
Thomas Jefferson University
Philadelphia, Pennsylvania 19107
*E-mail: prendergastg@mlhs.org
Selected reading
Aoki, M., Blazek, E., and Vogt, P.K. (2001). Proc.
Natl. Acad. Sci. USA 98, 136–141.
Dove, W. (2003). Nat. Genet. 34, 353–354.
Dragani, T.A. (2003). Cancer Res. 63,
3011–3018.
Gingras, A.C., Gygi, S.P., Raught, B.,
Polakiewicz, R.D., Abraham, R.T., Hoekstra,
M.F., Aebersold, R., and Sonenberg, N. (1999).
Genes Dev. 13, 1422–1437.
Gingras, A.C., Raught, B., and Sonenberg, N.
(2001). Genes Dev. 15, 807–826.
Jefferies, H.B., Fumagalli, S., Dennis, P.B.,
Reinhard, C., Pearson, R.B., and Thomas, G.
(1997). EMBO J. 16, 3693–3704.
Lazaris-Karatzas, A., and Sonenberg, N. (1992).
Mol. Cell. Biol. 12, 1234–1238.
Li, S., Sonenberg, N., Gingras, A.C., Peterson,
M., Avdulov, S., Polunovsky, V.A., and Bitterman,
P.B. (2002). Mol. Cell. Biol. 22, 2853–2861.
Polunovsky, V.A., Rosenwald, I.B., Tan, A.T.,
White, J., Chiang, L., Sonenberg, N., and
Bitterman, P.B. (1996). Mol. Cell. Biol. 16,
6573–6581.
Polunovsky, V.A., Gingras, A.C., Sonenberg, N.,
Peterson, M., Tan, A., Rubins, J.B., Manivel, J.C.,
and Bitterman, P.B. (2000). J. Biol. Chem. 275,
24776–24780.
Rajasekhar, V.K., Viale, A., Socci, N.D.,
Wiedmann, M., Hu, X., and Holland, E.C. (2003).
Mol. Cell 12, in press.
